SEC Filings

Form 10-K
XBIOTECH INC. filed this Form 10-K on 03/16/2018
Document Outline
Entire Document (2248.2 KB)
Subdocument 1 - 10-K - FORM 10-K
Page 1 - UNITED STATES
Page 2 - Documents incorporated by reference:
Page 3 - CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Page 4 - You should also read the matters described in the Risk Factors and the other cautionary statements m
Page 5 - Overview
Page 6 - Staphylococcus aureus
Page 7 - A Background on Therapeutic Antibodies
Page 8 - Fundamental Science of True Human Antibodies
Page 9 - Industry Context
Page 10 - Product Pipeline
Page 11 - The Lancet Oncology
Page 12 - Phase I Pancreatic Cancer Combination Study
Page 13 - Phase II Study for Hidradenitis Suppurativa (HS)
Page 14 - Intellectual Property
Page 15 - I. Treatment of Diabetes.
Page 16 - Employees
Page 17 - Risks Related to our Financial Condition and Capital Requirements
Page 18 - Raising additional capital may cause dilution to our existing shareholders, restrict our operations
Page 19 - Our future success is dependent on the regulatory approval and commercialization of our lead product
Page 20 - New laws or regulations may be promulgated or modified in the United States, in Europe, or other jur
Page 21 - We submitted a Marketing Authorization Application to the EMA for our lead product candidate after s
Page 22 - Because the results of earlier clinical trials are not necessarily predictive of future results, pro
Page 23 - Our lead product candidate or our other product candidates may cause undesirable side effects or hav
Page 24 - Even if our lead product candidate or our other product candidates receive regulatory approval, they
Page 25 - N/A
Page 26 - Failure to obtain regulatory approval in foreign jurisdictions would prevent our lead product candid
Page 27 - We have never marketed a drug before, and if we are unable to establish an effective sales force and
Page 28 - Our research programs may not succeed
Page 29 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 30 - We will need to expand our operations and grow the size of our organization in the future, and we ma
Page 31 - We depend on key personnel to operate our business, and many members of our current management team
Page 32 - Risks Related to Intellectual Property
Page 33 - Our technology may be found to infringe upon third-party intellectual property rights.
Page 34 - If we are unable to protect the confidentiality of our trade secrets, our business and competitive p
Page 35 - Insiders continue to have substantial control over our company since our initial public offering in
Page 36 - We may be a passive foreign investment company for US tax purposes which may negatively affect US in
Page 37 - We are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of
Page 38 - N/A
Page 39 - N/A
Page 40 - Market Information
Page 41 - N/A
Page 42 - AND RESULTS OF OPERATIONS
Page 43 - excluding
Page 44 - Results of Operations
Page 45 - General and Administrative
Page 46 - Other Income
Page 47 - Contractual Obligations and Commitments
Page 48 - Index to Financial Statements
Page 49 - Report of Independent Registered Public Accounting Firm
Page 50 - XBiotech Inc.
Page 51 - XBiotech Inc.
Page 52 - XBiotech Inc.
Page 53 - XBiotech Inc.
Page 54 - XBiotech Inc.
Page 55 - XBiotech Inc.
Page 56 - Research and Development Costs
Page 57 - Cash and Cash Equivalents
Page 58 - Property and Equipment
Page 59 - Net Loss per Share
Page 60 - 4. Accrued Expenses
Page 61 - 7. Net Loss Per Share
Page 62 - 8. Income Taxes
Page 63 - 9. Commitments and Contingencies
Page 64 - 10. Subsequent Events
Page 65 - 11. Selected Quarterly Financial Data (Unaudited)
Page 66 - Management's Evaluation of our Disclosure Controls and Procedures
Page 67 - PART IV
Page 68 - N/A
Page 69 - SIGNATURES
Page 70 - EXHIBIT INDEX
Page 71 - N/A
Subdocument 2 - EX-21.1 - EXHIBIT 21.1
Page 1 - Exhibit 21.1
Subdocument 3 - EX-23.1 - EXHIBIT 23.1
Page 1 - Exhibit 23.1
Subdocument 4 - EX-31.1 - EXHIBIT 31.1
Page 1 - Exhibit 31.1
Subdocument 5 - EX-31.2 - EXHIBIT 31.2
Page 1 - Exhibit 31.2
Subdocument 6 - EX-32.1 - EXHIBIT 32.1
Page 1 - Exhibit 32.1
Subdocument 7 - EX-32.2 - EXHIBIT 32.2
Page 1 - Exhibit 32.2
XBRL Item - EX-101.INS - XBRL INSTANCE FILE (What's this?)
XBRL Item - EX-101.SCH - XBRL SCHEMA FILE (What's this?)
XBRL Item - EX-101.CAL - XBRL CALCULATION FILE (What's this?)
XBRL Item - EX-101.DEF - XBRL DEFINITION FILE (What's this?)
XBRL Item - EX-101.LAB - XBRL LABEL FILE (What's this?)
XBRL Item - EX-101.PRE - XBRL PRESENTATION FILE (What's this?)
XBRL Viewer